The More Life Company advances U.S. compounded pharmaceutical pathway for Quicksome™

The More Life Company Corp. S. 503A compounding pharmacy to advance development, compounding and commercialization of Quicksome-enabled prescription compounded pharmaceutical products in the United States. S.

compounding capability for Quicksome by combining MLCO's proprietary formulation and delivery technology with the partner's compounding, formulation development, pharmacy, dispensing, national fulfillment and telemedicine capabilities. The company said it is initially assessing opportunities in hormone replacement, peptides and other active compounds, with scope to support a broader portfolio of Quicksome-enabled products. S. partner publicly at this stage while they focus on operational readiness, compounding implementation planning, early business development and finalizing definitive documentation.

Under the proposed arrangement, the parties would assess the development, compounding and commercialization in the United States of mutually approved Quicksome™-enabled prescription compounded pharmaceutical products. S. prescription-compounding field, with the specific terms to be detailed in definitive documentation. The parties plan to carry out due diligence, review implementation requirements and work toward definitive documentation.

The letter of intent is non-binding except for certain customary provisions. S. pathway for the development, compounding and commercialization of Quicksome-enabled prescription compounded pharmaceutical products across multiple therapeutic and wellness categories. S.

pharmacy infrastructure. The company said it is initially assessing hormone replacement, peptides and other active compounds where Quicksome could offer formulation, delivery, patient-experience or commercial advantages. S. pharmacy platform has national dispensing and fulfillment reach, along with existing relationships across healthcare and telemedicine channels.

The company also said it has begun selected discussions with prospective customers and commercial partners while operational readiness and definitive documentation progress. The LOI follows MLCO’s recently announced results from a third-party administered human pharmacokinetic study of United States Pharmacopeia (“USP”) grade testosterone formulated with the company’s Quicksome™ sublingual delivery technology. Management said the study provided an important new human validation point. For the Quicksome platform, the company said the work supports its ongoing efforts to develop differentiated hormone delivery approaches.

MLCO said the commercial opportunity could extend across hormones, peptides and other active compounds, while its broader Quicksome development work also includes applications such as CoQ10 and other molecules where improved delivery, stability, dose efficiency or user experience may create commercial value. Dennis Hancock, president and chief executive officer of The More Life Company, said the work with Quicksome has pointed the company toward a larger opportunity in compounded pharmaceuticals, and that the company also needs the compounding, pharmacy, dispensing and fulfillment infrastructure to bring those products to market.

Hancock said the company is not building around a single molecule or therapeutic category, adding that testosterone provides an important recent human validation point while the broader opportunity may extend across hormones, peptides and other active compounds where Quicksome may create meaningful differentiation. S. The More Life Company said compounding infrastructure and commercial channels together create what it called a significant new business-development opportunity. S.

commercialization pathway advances. MLCO said it is broadening discussions with telemedicine platforms, healthcare organizations, pharmaceutical developers and other commercial partners interested in evaluating Quicksome-enabled applications. S. partner plan to advance definitive documentation, operational readiness, detailed equipment and facility requirements, initial product prioritization and selected commercial discussions at the same time.

The company described Quicksome as its patented desiccated liposomal formulation and delivery technology. It said the platform uses proprietary formulation approaches and stabilizing molecules to encapsulate and formulate active ingredients into dosage formats designed to support rapid delivery, precision dosing and improved formulation performance. The company said it is advancing Quicksome across human health applications where formulation, stability, bioavailability and dose efficiency are relevant. Convenient, needle-free delivery may offer opportunities for innovation.

, says it is building an organization focused on implementing, licensing and reselling key technologies and formulations, including its patented Quicksome™ oral formulation and delivery technologies, its patented Quicksol™ solubility formulation technology and its licensed product reseller role for Agrarius™, a plant-signaling technology for agriculture. The company said its technologies are being applied to advanced delivery of molecules for human and husbandry animal uses, with work on products for pain management, weight loss, energy, focus, sleep, anxiety and other areas. It also said its Agrarius work is aimed at improving crop yields and reducing fertilizer usage.

The company said Quicksome™ uses proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats. The result is a The company says its new product formulations could deliver nutraceutical and drug molecules into the body faster, with greater impact, efficiency and accuracy. It says its patented Quicksol™ technology covers highly solubilized macrocyclic lactones that could be used in multiple viral applications with potential benefits for human and animal health globally.

The company also says its licensed Agrarius™ agricultural plant signaling technology is intended for crops to naturally increase yields, reduce fertilizer use and improve resilience to pests and climate change. The release includes a cautionary statement on forward-looking information under applicable securities laws. S. compounding pharmacy, as well as the establishment of dedicated Quicksome compounding capability in the United States.

It also refers to equipment, facility, environmental-control and implementation requirements, along with the timing and outcome of any on-site facility readiness. The company said it is also considering a Quicksome technology licensing model and reviewing possible hormone replacement, peptide, CoQ10 and other Quicksome-enabled applications for development, compounding and commercialization. Business-development discussions with prospective customers and commercial partners may also expand, and the release cites the potential commercial value, differentiation and market opportunities tied to Quicksome-enabled products.

The forward-looking information reflects management’s expectations, assumptions and beliefs as of the date of the release and is subject to known and unknown risks, uncertainties and other factors that could cause actual results, performance or outcomes to differ. The company said a range of factors could cause actual developments to differ materially from forward-looking statements, including the parties’ ability to negotiate and sign definitive documents, the outcome of facility, equipment and operational-readiness assessments, and regulatory, pharmacy, compounding and other requirements for the planned products and activities.

It also cited future formulation, validation and development work, customer and market acceptance, the availability of capital, commercial partners and other resources, and other risks tied to developing and commercializing pharmaceutical, nutraceutical and delivery technologies. S. compounding capability will be established on the timing or terms currently expected, that any Quicksome-enabled formulation will be developed or commercialized, that prospective business-development talks will lead to commercial arrangements, or that any Quicksome™ formulation will receive the required regulatory authorization or gain commercial adoption.

The company said readers should not place undue reliance on forward-looking information in the news release, which reflects its expectations as of the date of the release and may change afterward. It added that it does not intend or undertake any obligation to update or revise forward-looking information, except as required by applicable securities legislation. The company also said neither the CSE nor OTC Markets Group has reviewed or approved the contents of the press release. Further information: Dennis Hancock, President and Chief Executive Officer, The More Life Company Corp.

Investor relations: 647-725-9755. company.